These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 23799873)

  • 1. A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial.
    Witzens-Harig M; Memmer ML; Dreyling M; Hess G
    BMC Cancer; 2013 Jun; 13():308. PubMed ID: 23799873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
    van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
    J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.
    Gisselbrecht C; Glass B; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Ketterer N; Shpilberg O; Hagberg H; Ma D; Brière J; Moskowitz CH; Schmitz N
    J Clin Oncol; 2010 Sep; 28(27):4184-90. PubMed ID: 20660832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation.
    Cuccuini W; Briere J; Mounier N; Voelker HU; Rosenwald A; Sundstrom C; Cogliatti S; Hirchaud E; Ysebaert L; Bron D; Soulier J; Gaulard P; Houlgatte R; Gisselbrecht C; Thieblemont C
    Blood; 2012 May; 119(20):4619-24. PubMed ID: 22408263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.
    Mey UJ; Olivieri A; Orlopp KS; Rabe C; Strehl JW; Gorschlueter M; Hensel M; Flieger D; Glasmacher AG; Schmidt-Wolf IG
    Leuk Lymphoma; 2006 Dec; 47(12):2558-66. PubMed ID: 17169800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial.
    Witzens-Harig M; Viardot A; Keller U; Wosniok J; Deuster O; Klemmer J; Geueke AM; Meißner J; Ho AD; Atta J; Marks R; La Rosée P; Buske C; Dreyling MH; Hess G
    Hemasphere; 2021 Oct; 5(10):e636. PubMed ID: 34589671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Martín A; Redondo AM; Dlouhy I; Salar A; González-Barca E; Canales M; Montes-Moreno S; Ocio EM; López-Guillermo A; Caballero D;
    Br J Haematol; 2016 Apr; 173(2):245-52. PubMed ID: 26847165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab combined with DexaBEAM followed by high dose therapy as salvage therapy in patients with relapsed or refractory B-cell lymphoma: mature results of a phase II multicentre study.
    Kirschey S; Flohr T; Wolf HH; Frickhofen N; Gramatzki M; Link H; Basara N; Peter N; Meyer RG; Schmitz N; Weidmann E; Banat A; Schulz A; Kolbe K; Derigs G; Theobald M; Hess G
    Br J Haematol; 2015 Mar; 168(6):824-34. PubMed ID: 25546611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.
    del Rio MS; Choquet S; Hoang-Xuan K; Glaisner S; Fourme E; Janvier M; Soussain C
    J Neurooncol; 2011 Nov; 105(2):409-14. PubMed ID: 21656329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?
    Gisselbrecht C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():410-6. PubMed ID: 23233612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
    Hagberg H; Gisselbrecht C;
    Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.
    Kambhampati S; Hunter B; Varnavski A; Fakhri B; Kaplan L; Ai WZ; Pampaloni M; Huang CY; Martin T; Damon L; Andreadis CB
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):246-256.e2. PubMed ID: 33288485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
    Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.
    Matasar MJ; Czuczman MS; Rodriguez MA; Fennessy M; Shea TC; Spitzer G; Lossos IS; Kharfan-Dabaja MA; Joyce R; Fayad L; Henkel K; Liao Q; Edvardsen K; Jewell RC; Fecteau D; Singh RP; Lisby S; Moskowitz CH
    Blood; 2013 Jul; 122(4):499-506. PubMed ID: 23692856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.
    Colosia A; Njue A; Trask PC; Olivares R; Khan S; Abbe A; Police R; Wang J; Ruiz-Soto R; Kaye JA; Awan F
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):343-355.e6. PubMed ID: 24768510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal renal toxicity after Rituximab DHAP with a modified cisplatin application scheme in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Lisenko K; McClanahan F; Schöning T; Schwarzbich MA; Cremer M; Dittrich T; Ho AD; Witzens-Harig M
    BMC Cancer; 2016 Apr; 16():267. PubMed ID: 27067641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma.
    Gisselbrecht C; Schmitz N; Mounier N; Singh Gill D; Linch DC; Trneny M; Bosly A; Milpied NJ; Radford J; Ketterer N; Shpilberg O; Dührsen U; Hagberg H; Ma DD; Viardot A; Lowenthal R; Brière J; Salles G; Moskowitz CH; Glass B
    J Clin Oncol; 2012 Dec; 30(36):4462-9. PubMed ID: 23091101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
    Witzig TE; Geyer SM; Kurtin PJ; Colgan JP; Inwards DJ; Micallef IN; LaPlant BR; Michalak JC; Salim M; Dalton RJ; Moore DF; Reeder CB;
    Leuk Lymphoma; 2008 Jun; 49(6):1074-80. PubMed ID: 18569634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.